What Integra LifeSciences (IART) Said on Its Q3 Earnings Call

Integra LifeSciences (IART) reported Q3 revenue of $304.1M, with neurosurgery growing 6.5% organically. Tissue Reconstruction revenue declined 2.2% to $107.1M. The company reaffirmed its full-year revenue outlook of $1.634B-$1.654B but reduced the midpoint by $30M. It expects 2027 revenue and EPS growth, supported by SurgiMend relaunch and PriMatrix momentum. Net debt was $1.5B at quarter-end, with leverage at 3.8x.

Original reporting
Published Oct 21, 2026, 4:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 4:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The lowered guidance and added financing costs create near‑term downside risk, but 2027 growth initiatives may offset long‑term concerns.

02

Market read

First‑report earnings and financing disclosure for a mid‑cap med‑tech firm, likely to move the stock today.

03

What to watch

Potential upside from upcoming SurgiMend label expansion and international sales momentum.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Integra LifeSciences (NASDAQ:IART) provides neurosurgery and tissue reconstruction products. The Q3 earnings call highlighted mixed segment performance and a recent $2.1B refinancing.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences reported Q3 results, lowered full-year revenue guidance by $30M and disclosed a $2.1B refinancing that adds $8M interest expense in Q4.

Expected impact

likely downside as market prices in lower revenue outlook and added interest expense

Evidence & confidence

The earnings call disclosed fresh guidance and financing details that were not previously public, providing a clear catalyst for price movement.

Market effects

Medical device sector may see modest pressure as Integra's guidance downgrade signals demand softness in tissue reconstruction.

U.S. healthcare stocks could face slight pullback in the short term.

Limited to U.S. listed med‑tech equities; no broader macro impact.

Counterpoint

If the refinancing improves balance sheet flexibility, the stock could rebound on longer‑term growth prospects.

Key entities

  • Integra LifeSciences

    Medical device manufacturer reporting Q3 results and guidance.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.